Six mutations in AAGAB confirm its pathogenic role in Chinese punctate palmoplantar keratoderma patients.
Hongzhou Cui,Min Gao,Wenjun Wang,Ruo Xiao,Gang Chen,Qing Zhang,Hongyang Fu,Yi Zhou,Birong Guo,Ying Dong,Jie Shen,Min Zhang,Zhen Yue,Fengxia Liu,Da Lin,Tianwen Gao,Anping Zhang,Wenming Zhou,Liangdan Sun,Sen Yang,Jun Wang,Yong Cui,Xuejun Zhang
DOI: https://doi.org/10.1038/jid.2013.198
2013-01-01
Abstract:TO THE EDITOR Palmoplantar keratodermas (PPKs) are a group of rare keratinization disorders characterized by the excessive formation of keratin on the palms and soles. Four clinical types of PPK can be classified by the pattern of lesions: diffuse, punctuate, focal, and striate (Stevens et al., 1996). Punctate palmoplantar keratoderma type I (PPKP1, MIM number 148,600) is an autosomal dominant inherited subtype of PPK characterized by multiple tiny punctate keratoses on the palms and soles, which can gradually increase in diameter with age and even coalesce (Figure 1a and b). The incidence of this disease was reported as 1.17 per 100,000 population in Croatia and 3.3 per 100,000 population in Slovenia (Guo et al., 2012). Two linkage loci for PPKP1 (8q24.13–8q24.21, 15q22.2–15q24.1) have been reported previously (Martinez-Mir et al., 2003; Zhang et al., 2004; Gao et al., 2005; El Amri et al., 2010; Mamai et al., 2012). In recent years, the success of exome sequencing has been well established in the identification of novel causal mutations for Mendelian diseases (Ku et al., 2012). Here, we subjected two DNA sequences (III8 and III9) from the Chinese PPKP1 family linked to 15q22 (Family 22) to exome sequencing. Informed consent was obtained from all the sequenced participants. This study was authorized by the Ethics Committee of Anhui Medical University and was conducted in accordance with the Declaration of Helsinki Principles. Exome capture and enrichment were performed using the Agilent SureSelect Human All Exon Kit (in solution; Santa Clara, CA) according to the manufacturer’s protocols. Exome sequencing was then performed on a HiSeq 2000 platform (Illumina, San Diego, CA), and sequence data were processed to raw sequence reads. These reads were aligned to a human reference genome (NCBI build 37.3, hg19), and the analytical pipeline was then followed by SOAPsnp (Li et al., 2009). Finally, the variants were annotated to obtain information such as genomic position and functional effect. On average, two sequences were obtained from each individual at ~50-fold coverage depth. We obtained 4.51 billion bases of sequence data as paired-end, 90-bp reads. After discarding reads that had a duplicated start site, 2.69 billion bases of mappable targeted exome were defined by RefSeq genes. An average of 89.2% of the exome was covered at least ~10-fold, and 51,819 variants were identified per individual. We primarily focused on coding variants, including non-synonymous variants, splice-site variants, and insertions/deletions, of which there were an average of 11,362. We filtered the variants against dbSNP129, eight HapMap individuals, the 1,000 Genomes Project, the YH database, and unaffected individual, and reduced the number of candidate variants to 527. We then used SIFT to predict the functional impact and determine the 261 variants that were the most likely to be damaging. Finally, we found that five mutations in five genes (DAPK2, IGDCC4, RPL4, TPM1, and AAGAB) were located on 15q22.2–15q24.1. Among the five genes, mutations in AAGAB have recently been identified in PPKP1 in two publications (Giehl et al., 2012; Pohler et al., 2012). We tested all the samples and identified the c.552_554TAG>AT mutation in exon 6 of AAGAB as the causative mutation in Family 22 (Figure 1c and d). This mutation resulted in a stop codon at amino acid position 188 (p.Phe184 Leufs* 6). We then sequenced all the exons and exon–intron boundaries of AAGAB in 59 individuals from an additional seven families (Families 23–29) and 28 sporadic patients (Sporadic patients 1–28) with PPKP1 (Supplementary Figure S1 online). Finally, four truncated mutations in four respective families and a splice-site mutation in one sporadic case were identified (Supplementary Figure S2 online). The AAGAB gene mutations were absent in three other PPKP1 families (Families 27–29) and 27 sporadic patients (Sporadic patients 2–28). In addition, we identified the c.481C>T mutation in exon 5 in one patient with cancer from Family 24, whereas none of three sporadic patients with cancer carried mutations. There appeared to be no genetic link between AAGAB mutations and cancer. To date, fourteen mutations in AAGAB have been identified in PPKP1 patients with different ancestries, including Scottish, Irish, Japanese, Tunisian, Croatian, German, and Chinese origins (Giehl et al., 2012; Pohler et al., 2012). Table 1 lists all mutation types and the categorized domain proteins. The positions of protein alterations are shown (Supplementary Figure S3 online). These data further indicate that AAGAB is a major genetic factor in PPKP1. AAGAB encodes α- and γ-adaptin-binding protein p34, which contains 315 amino acids. An immunolocalization study revealed that p34 usually acts as a ligand for the NH2-terminal domains of α-adaptin and γ-adaptin. These two adaptins are present in two types of soluble adaptor complexes, AP-1 and AP-2. p34 can colocalize with cytosolic AP-1/AP-2 to help recruit soluble adaptors to membranes (Page et al., 1999). In addition, AP-2 acts as a ligand for the EGFR, which has been implicated in entry into the endosomal system (Rappoport and Simon 2009). Studies have revealed that AAGAB knockdown in HaCaT cells increases active EGFR signaling by >20-fold and that p34 deficiency inhibits binding with cytosolic AP-2, decreases EGFR protein turnover, and recycles the receptor to the cell surface (Pohler et al., 2012). EGFR appears to be closely associated with p34 to balance the normal endocytic recycling of receptor tyrosine kinases, which have been implicated in the regulation of cell proliferation. In the current study, we identified six mutations in the AAGAB gene in Chinese PPKP1 patients. However, the gene collectively accounts for only a fraction of cases. Other genes carrying mutations will be identified in the unresolved patients. As the widespread and cost-effective use of exome sequencing increases, it is proving to be a powerful strategy for identifying specific mutations in individuals. The authors state no conflict of interest. We are most grateful to all the patients with PPK and their family members for participating in this study. This study was supported by the National Natural Science Foundation of China (grant nos. 31100907 and 31171223), Program for New Century Excellent Talents in University (NCET-11-0889), Science and Technological Foundation of Anhui Province for Outstanding Youth (1108085J10) and Pre-project of State Key Basic Research Program 973 of China (no. 2012CB722404), and the Ministry of Education of China (IRT-1046). SUPPLEMENTARY MATERIAL Supplementary material is linked to the online version of the paper